Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast

Abstract The increased spread of drug-resistant malaria highlights the need for alternative drugs for treatment and chemoprophylaxis. The combination of atovaquone‐proguanil (Malarone®) has shown high efficacy against Plasmodium falciparum with only mild side-effects. Treatment failures have been at...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Wurtz Nathalie, Pascual Aurélie, Marin-Jauffre Adeline, Bouchiba Housem, Benoit Nicolas, Desbordes Marc, Martelloni Maryse, de Santi Vincent, Richa Georges, Taudon Nicolas, Pradines Bruno, Briolant Sébastien
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2012
Subjects:
Malaria
Plasmodium falciparum
Malarone®
Atovaquone-proguanil
Cytochrome b
Resistance
Clinical failure
in vitro
Anti-malarial drug
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
Online Access:https://doi.org/10.1186/1475-2875-11-146
https://doaj.org/article/ece5613526434581b5998913a8cc0ba2
Description
Summary:Abstract The increased spread of drug-resistant malaria highlights the need for alternative drugs for treatment and chemoprophylaxis. The combination of atovaquone‐proguanil (Malarone®) has shown high efficacy against Plasmodium falciparum with only mild side-effects. Treatment failures have been attributed to suboptimal dosages or to parasite resistance resulting from a point mutation in the cytochrome b gene. In this paper, a case of early treatment failure was reported in a patient treated with atovaquone-proguanil; this failure was not associated with a mutation in the parasite cytochrome b gene, with impaired drug bioavailability, or with re-infection.

Similar Items